Holen Sie sich die Stockscreener-App
4.98
14.49%
0.63
Schlusskurs vom Vortag:
$4.35
Offen:
$4.39
24-Stunden-Volumen:
379.61K
Relative Volume:
0.26
Marktkapitalisierung:
$91.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+87.24%
1M Leistung:
+453.39%
6M Leistung:
+333.09%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.25
$5.07
1-Wochen-Bereich:
$2.43
$6.19
52-Wochen-Spanne:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Vergleichen Sie CTOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
4.995 | 91.59M | 0 | 0 | 0 | 0.00 |
|
RGC
Regencell Bioscience Holdings Ltd
|
16.13 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.95 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.43 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.68 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria
Citius Oncology On Track to Launch Lymphir in US in H2 - MarketScreener
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - StreetInsider
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citadel Advisors LLC Makes New $26,000 Investment in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Cantech Letter
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharmaceuticals Secures $15.8M Strategic Financing: LYMPHIR Commercial Launch Gets Green Light - Stock Titan
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com South Africa
Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health - MarketScreener
Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir - marketscreener.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com South Africa
Citius Oncology stock soars on distribution deal - Investing.com
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance
Citius Oncology (NASDAQ:CTOR) Trading Up 3.4% – Here’s Why - Defense World
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals Reports Critical Cash Position, Advances FDA-Approved LYMPHIR Launch Strategy - Stock Titan
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
Citius Oncology IncReceives Nasdaq Notice For Bid Price Non-ComplianceSEC Filing - marketscreener.com
Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy? - Defense World
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Oncology Inc (NASDAQ: CTOR) Is On The Fall - stocksregister.com
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com India
Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 4/1/25 - TipRanks
Why Citius Oncology Inc. Stock Spiked Over 7%? - timothysykes.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):